CISplatin (75mg/m^2) + Etoposide Therapy-21 day

INDICATIONS FOR USE:

INDICATION	ICD10	Regimen Code	Reimbursement status
Small cell lung cancer (SCLC) extensive disease	C34	00280a	Hospital

TREATMENT:

The starting dose of the drugs detailed below may be adjusted downward by the prescribing clinician, using their independent medical judgement, to consider each patients individual clinical circumstances.

CISplatin is administered on day 1 and etoposide is administered on three consecutive days (Days 1-3) of a 21 day cycle for 4-6 cycles.

Facilities to treat anaphylaxis MUST be present when the chemotherapy is administered.

Admin Order	Day	Drug	Dose	Route	Diluent & Rate	Cycle
1	1, 2 & 3	Etoposide	100mg/m^2	IV Infusion	1000ml 0.9% NaCl over 60mins	Every 21 days for 4-6 cycles
2	1	CISplatin[b]	[a]75mg/m^2	IV Infusion	1000ml 0.9% NaCl over 2 hours	Every 21 days for 4-6 cycles

[a]The total dose of CISplatin may be fractionated and given over 3 days i.e. 25mg/m^2 on day 1

[b]**Pre and post hydration therapy required for CISplatin**
See local hospital policy recommendations.
Suggested prehydration for CISplatin therapy:

1. Administer 10mmol magnesium sulphate ($MgSO_4$) ((+/-KCl 20mmol/L if indicated) in 1000 mL sodium chloride 0.9% over 60 minutes.

Administer CISplatin as described above
Post hydration: Administer 1000ml 0.9% NaCl over 60mins
Mannitol 10% may be used to as per local policy to induce diuresis, although there is no conclusive evidence that this is required. The routine use of furosemide to increase urine flow is not recommended unless there is evidence of fluid overload.(2,3)

In cases of CISplatin toxicity or poorly functioning patients or age > 75 CARBOplatin AUC 5 (Dose = AUC x (GFR +25)) administered on Day 1 only may be substituted.

ELIGIBILTY:

- Indications as above
- ECOG status 0-3
- Life expectancy > 3 months

EXCLUSIONS:

- Hypersensitivity to etoposide, CISplatin or any of the excipients.
- CISplatin
  - Pre existing neuropathies ≥ grade 2
  - Creatinine clearance < 60 mL/min
  - Significant hearing impairment/tinnitus
- Severe liver impairment (etoposide)

- Pregnancy
- Breast Feeding

PRESCRIPTIVE AUTHORITY:

The treatment plan must be initiated by a Consultant Medical Oncologist.

TESTS:

Baseline tests:

- Blood, renal and liver profile
- Audiology and creatinine clearance if clinically indicated

Regular tests:

- Blood, renal and liver profile prior to each cycle

Disease monitoring:

Disease monitoring should be in line with the patient's treatment plan and any other test/s as directed by the supervising Consultant.

DOSE MODIFICATIONS:

- Any dose modification should be discussed with a Consultant

Haematological:

Table 1: Dose modification of etoposide for haematological toxicity

ANC (x 10^9/L)		Platelets (x 10^9/L)	Dose Etoposide
≥1.5	**and**	≥100	100%
1-1.49	**or**	75-99	75%
<1	**or**	<75	DELAY

Renal and Hepatic Impairment:

Table 2: Dose modification of CISplatin and etoposide in renal and hepatic impairment

Drug	Renal impairment		Hepatic Impairment			
Etoposide	**CrCl (ml/min)**	**Dose**	**Bilirubin (micromol/L)**		**AST (Units/L)**	**Dose**
	>50	100%	26-51	or	60-180	50%
	15-50	75%	>51	or	>180	Clinical decision
	<15	50%				
	Subsequent dosing should be based on patient tolerance and clinical effect.					
CISplatin	**CrCl (ml/min)**	**Dose**	No dose reduction necessary			
	≥60	100%				
	45-59	75%				
	<45	Consider CARBOplatin/Clinical decision				

Table 3: Dose modification of CISplatin and etoposide for adverse events

Adverse reactions	Recommended dose modification
Grade ≥ 2 peripheral neuropathy	Substitute CARBOplatin AUC 5 or 50% reduction of CISplatin dose after recovery to grade ≤ 1; 100% dose of etoposide.
Grade 3 (Other than mucositis or alopecia)	Delay until recovery to Grade 1. Then reduce dose of CISplatin and etoposide to 75%.

SUPPORTIVE CARE:

EMETOGENIC POTENTIAL:

CISplatin High **(Refer to local policy).**
Etoposide Low **(Refer to local policy).**

PREMEDICATIONS:

Hydration prior and post CISplatin administration **(Refer to local policy or see recommendations above).**

OTHER SUPPORTIVE CARE: No specific recommendations

ADVERSE EFFECTS / REGIMEN SPECIFIC COMPLICATIONS:

The adverse effects listed are not exhaustive. Please refer to the relevant Summary of Product Characteristics for full details.

- **Neutropenia**: Fever or other evidence of infection must be assessed promptly and treated appropriately. Avoid aminoglycoside antibiotics.
- **Renal Toxicity**: Nephrotoxicity is common with CISplatin. Strongly encourage oral hydration. If oral hydration is not possible (e.g. excessive nausea), IV hydration is indicated. Avoid nephrotoxic drugs such as aminoglycoside antibiotics where possible. Where treatment with nephrotoxic drugs must be used,

monitor renal function.

- **Ototoxicity and sensory neural damage**: These are associated with CISplatin therapy. They should be assessed by history prior to each cycle.
- **Hypersensitivity:** Hypersensitivity reactions have been reported with etoposide and CISplatin. Monitor infusion of etoposide for the first 15 minutes for signs of hypotension.

DRUG INTERACTIONS:

- CISplatin may potentiate the nephrotoxic and ototoxic effects of loop diuretics and aminoglycosides so concurrent use should be avoided.
- Concomitant CISplatin therapy is associated with reduced total body clearance of etoposide.
- CYP3A4 inducers may increase the clearance of etoposide.
- CYP3A4 and p-gp inhibitors may decrease the clearance of etoposide
- Current drug interaction databases should be consulted for more information

ATC CODE:

CISplatin	L01XA01
Etoposide	L01CB01

REFERENCES:

1. Evans WK, Shepherd FA, Feld R, et al. VP-16 and CISplatin as first-line therapy for small-cell lung cancer. J Clin Oncol 1985; 3(11):1471-7.
2. Nephrotoxicity Associated with CISplatin EviQ ID: 184 v.3 https://www.eviq.org.au/clinical-resources/side-effect-and-toxicity-management/prophylaxis-and-prevention/184-nephrotoxicity-associated-with-CISplatin
3. Portilla D et al. CISplatin nephrotoxicity. UptoDate Accessed August2019 https://www.uptodate.com/contents/cisplatin-nephrotoxicity
4. Pujol JL, Carestia L, Daures JP. Is there a case for CISplatin in the treatment of small-cell lung cancer? A meta- analysis of randomized trials of a CISplatin-containing regimen versus a regimen without this alkylating agent. Br J Cancer 2000 Jul;83(1):8-15.
5. Eloxatin ®Summary of Product Characteristics HPRA.Last updated: 11/03/2019. Accessed August 2019 Available at: https://www.hpra.ie/img/uploaded/swedocuments/Final%20approved%20SPC%20PA0822.199.001.pdf
6. Etoposide 20 mg/ml Concentrate for Solution for Infusion Summary of Product Characteristics. HPRA Last updated: 29/07/2019 Accessed August 2019 Available at https://www.hpra.ie/img/uploaded/swedocuments/Licence_PA2059-036-001_29072019103821.pdf
7. NCCP Classification Document for Systemic Anti-Cancer Therapy (SACT) Induced Nausea and Vomiting. V1 2018. https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/nccp%20antiemetic%20classification%20document%20v1%202018.pdf

Version	Date	Amendment	Approved By
1	10/09/2015		Dr Maccon Keane
2	20/09/2017	Updated title and dosing in renal impairment, applied new NCCP regimen template	Prof Maccon Keane
3	08/01/2019	Updated hydration protocol for CISplatin	Prof Maccon Keane
4	04/09/2019	Reviewed. Update of etoposide renal dosing	Prof Maccon Keane

Comments and feedback welcome at oncologydrugs@cancercontrol.ie.